We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.
Hans Peter joined the Board of Shield Therapeutics plc in July 2018. Mr. Hasler was the Chief Executive Officer of Vicarius Pharma AG, a privately held European Bio-Pharma company until 2020. His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International. Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and beforehand Managing Director of Wyeth Group Germany, Münster.
Hans Peter Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Minerva Neurosciences in Boston (Nasdaq) and Gain Therapeutics, Bethesda (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.
Member of the Audit Committee and Nomination Committee.
Greg Madison is a seasoned executive who brings strong operating experience and a track record of success leading small to medium size organisations. Prior to joining Shield, he was Chief Executive Officer at Melt Pharmaceuticals in Boston, MA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia. Prior to Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organisation from development stage to commercial stage focused on Auryxia, an oral product for the treatment of hyperphosphatemia and iron deficiency anaemia, and ultimately leading to a merger with Akebia Therapeutics. In 2013 and 2014, he was Chief Commercial Officer at AMAG Pharmaceuticals where he was closely involved with Feraheme, a leading intravenous product for the treatment of iron deficiency. From 2000-2012, Greg was at Genzyme Corporation, ultimately serving as Vice President and General Manager of its Nephrology Division, where he led a division that had revenues in excess of $1 billion dollars, led by the world’s leading phosphate binder, Renvela. Greg began his career as a sales representative for Janssen Pharmaceuticals, a division of Johnson and Johnson.
Peter has over 25 years’ experience in international M&A deals, company turnarounds, licensing transactions and financing activities including IPOs with particular experience in chemical and healthcare industries. He is currently CEO/CFO of Apeiron Biologics AG. Peter was CFO/CBO of Medigene AG between 2012 and 2016 and was fundamental in the turnaround process by out licensing marketed and legacy products and enhancing shareholder value with a new large international investor base. Prior to that he was CFO of Wilex AG, having orchestrated its IPO in 2006. Peter read Business Management, Banking, Marketing and Controlling in London, St. Gallen and Munich, and has a certificate in Business Studies from the University of London.
Member of the Audit Committee and Nomination Committee.
Christian is one of the founders of Shield Therapeutics where he was responsible for the discovery and initial clinical development programs until 2012. He is an entrepreneurial senior medical affair, and clinical development executive with vast experience in both large and small pharmaceutical companies. He serves in various boards and will focus on Shield Therapeutics medical, and scientific strategy. He is Managing Director of his own boutique consultancy business TACHRIS AG in Switzerland providing clinical, medical, medical marketing and strategic management consultancy services including pharmaceutical asset evaluation.
Dr Schweiger is also Lecturing Professor in Pharmaceutical Medicine at the University of Essen and actively working with different international patient and professional associations.
Mrs Lacerca-Allen is currently Senior Vice President, Chief Compliance Officer at Aimmune Therapeutics based in San Francisco, California (a Nestlé Health Science Corporation since October 2020). She brings to Shield extensive experience in compliance having started and implemented compliance programmes at several major pharmaceutical companies including Merck, Sharp & Dohme, Bristol-Myers Squibb Company, Mylan Laboratories and Elan Pharmaceuticals. Mrs Lacerca-Allen was also a non-executive director at ArthroCare Corporation, a publicly traded company in the medical device sector prior to its acquisition by Smith & Nephew in 2014. Fabiana holds a masters in law from the University of California, a Doctor in Law and a Bachelor in Law from the Universidad de Buenos Aires and is the recipient of several international recognitions and has been published extensively in areas of leadership and compliance. Mrs Lacerca-Allen will become a member of the Group’s Audit Committee.
Anders brings over 30 years of global pharmaceutical/biotech experience. He is currently Executive Vice President and Chief Commercial Officer at Banner Life Sciences where he is planning and executing a US launch of a novel treatment of Multiple Sclerosis. He has previously held senior commercial and general management roles in AstraZeneca, Biogen, Orexo AB, where he was President and CEO, EMD Serono, and Santhera Pharmaceuticals. Anders holds a MSc in Pharmacy from Uppsala University and a Diploma in Business Administration from IHM, Stockholm. He will join the Remuneration Committee, replacing Rolf Hoffmann who, as previously announced, is not seeking re-election at the next Annual General Meeting.